Key Takeaways:
- Next-Gen Cancer Tech: Lilly is betting on in vivo CAR-T technology, which programs immune cells to fight cancer directly inside the body, bypassing the slow, costly lab-based methods used today.
- Streamlined Treatment: The goal is to create “off-the-shelf” therapies that eliminate the weeks of waiting time required for current treatments from rivals like Gilead and Novartis.
- Strategic Portfolio Growth: This is Lilly’s third acquisition in a year focused on genetic and RNA-based platforms, targeting aggressive blood cancers like multiple myeloma.
Eli Lilly Strikes Deal to acquire Kelonia Therapeutics in a transaction valued at up to $7 billion. The move is designed to strengthen Eli Lilly’s early-stage cancer pipeline and accelerate the development of next-generation immune therapies that could simplify treatment delivery.
Eli Lilly Strikes Deal that positions the company to compete more aggressively with major drugmakers in the fast-growing CAR-T cancer therapy market by supporting a new approach designed to work directly inside the body.
Lilly Targets Simpler, Faster Cancer Treatments
Kelonia is developing therapies that reprogram T cells inside the body to attack cancer, a method known as in vivo CAR-T. The approach seeks to overcome limitations of traditional CAR-T therapies, which require extracting and modifying a patient’s cells in a lab.
Those existing treatments, developed by companies including Gilead Sciences, Novartis, Bristol Myers Squibb and Johnson & Johnson, are customized for each patient and can take weeks to produce.
Kelonia’s lead drug, KLN-1010, is currently in Phase 1 trials targeting multiple myeloma, an aggressive blood cancer. The company also has several preclinical programs in development.
“Kelonia’s in vivo platform has the potential to deliver rapid, durable responses in a far simpler, off-the-shelf format,” said Jacob Van Naarden, president of Lilly Oncology, in a statement.
Eli Lilly Strikes Deal as the company notes that Kelonia’s approach could help reduce the risks associated with traditional CAR-T therapies, such as cytokine release syndrome, while also speeding treatment timelines.
Analysts See Growing Pharma Interest in CAR-T Innovation
Industry analysts say the acquisition reflects intensifying competition among major drugmakers to advance cell-based cancer therapies.
David Risinger, an analyst at Leerink Partners, noted that Kelonia has ongoing collaborations with Astellas Pharma and Johnson & Johnson to develop similar in vivo CAR-T technologies.
He added that Lilly has made three acquisitions in under a year, focused on in vivo platforms. The company previously bought Verve Therapeutics for gene-editing technology and Orna Therapeutics for RNA-based drugs.
Eli Lilly Strikes Deal that, according to RBC Capital Markets analyst Leonid Timashev, underscores strong industry interest in therapies targeting BCMA, a protein found on most multiple myeloma cells.
A BCMA-focused CAR-T therapy developed by Legend Biotech and Johnson & Johnson, known as Carvykti, is already on the market.
Timashev said the deal also suggests existing CAR-T therapies may be undervalued, citing growing sales potential in the coming years.
Market Reaction and Strategic Implications
Lilly shares closed down 0.8% at $919.90 following the announcement, reflecting a muted immediate market response to the acquisition.
Eli Lilly Strikes Deal that highlights the company’s broader push to strengthen its oncology portfolio as global demand for advanced cancer treatments continues to rise.
Experts say in vivo CAR-T technology could reshape the market if it proves effective, offering faster, more scalable treatments compared with current methods.
Still, the therapies remain in early stages of development, and clinical success is not guaranteed. Companies will need to demonstrate safety and effectiveness in larger trials before seeking regulatory approval.
If successful, the approach could expand access to CAR-T therapies by reducing costs and complexity, potentially benefiting a wider group of patients.
Visit Healthcare 360 Magazine For The Most Recent Information.
